ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Design, Synthesis, and Biological Evaluation of Doxorubicin−Formaldehyde Conjugates Targeted to Breast Cancer Cells

View Author Information
Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309-0215
Cite this: J. Med. Chem. 2004, 47, 5, 1193–1206
Publication Date (Web):January 24, 2004
https://doi.org/10.1021/jm030352r
Copyright © 2004 American Chemical Society

    Article Views

    2547

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options
    Supporting Info (2)»

    Abstract

    Abstract Image

    The anthracycline antitumor drug doxorubicin (DOX) has been utilized for decades as a broad-spectrum chemotherapeutic. Recent literature evidence documents the role of formaldehyde in the cytotoxic mechanism, and anthracycline−formaldehyde conjugates possess substantially enhanced activity in vitro and in vivo. Targeting a doxorubicin−formaldehyde conjugate specifically to cancer cells may provide a more efficacious chemotherapeutic. The design and 11-step synthesis of doxorubicin−formaldehyde conjugates targeted to the estrogen receptor, which is commonly overexpressed in breast cancer cells, are reported. The formaldehyde is incorporated in a masked form as an N-Mannich linkage between doxorubicin and salicylamide. The salicylamide triggering molecule, previously developed to release the doxorubicin−formaldehyde active metabolite, is tethered via derivatized ethylene glycols to an E and Z mixture of 4-hydroxytamoxifen. The targeting group, E/Z-4-hydroxytamoxifen, was selected for its ability to tightly bind the estrogen receptor and antiestrogen binding sites. The targeted doxorubicin−formaldehyde conjugates' estrogen receptor binding and in vitro growth inhibition were evaluated as a function of tether length. The lead compound, DOX-TEG-TAM, bearing a triethylene glycol tether, binds the estrogen receptor with a binding affinity of 2.5% relative to E/Z-4-hydroxytamoxifen and inhibits the growth of four breast cancer cell lines with 4-fold up to 140-fold enhanced activity relative to doxorubicin.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    *

     To whom correspondence should be addressed. Phone:  303-492-6193. Fax:  303-492-5894. E-mail:  [email protected].

    Supporting Information Available

    ARTICLE SECTIONS
    Jump To

    1H NMR spectra for all isolated intermediates and final products used in the biological evaluation; HPLC data for establishing degree of purity. This material is available free of charge via the Internet at http://pubs.acs.org.

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

    Cited By

    This article is cited by 44 publications.

    1. Carine M. Abdelmalek, Zexi Hu, Thales Kronenberger, Jenni Küblbeck, Franziska J. M. Kinnen, Salma S. Hesse, Afsin Malik, Mark Kudolo, Raimund Niess, Matthias Gehringer, Lars Zender, Paula A. Witt-Enderby, Darius P. Zlotos, Stefan A. Laufer. Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry 2022, 65 (6) , 4616-4632. https://doi.org/10.1021/acs.jmedchem.1c01646
    2. Chu Tang, Yang Du, Qian Liang, Zhen Cheng, Jie Tian. A Novel Estrogen Receptor α-Targeted Near-Infrared Fluorescent Probe for in Vivo Detection of Breast Tumor. Molecular Pharmaceutics 2018, 15 (10) , 4702-4709. https://doi.org/10.1021/acs.molpharmaceut.8b00684
    3. Chu Tang, Changhao Li, Silong Zhang, Zhiye Hu, Jun Wu, Chune Dong, Jian Huang, and Hai-Bing Zhou . Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer. Journal of Medicinal Chemistry 2015, 58 (11) , 4550-4572. https://doi.org/10.1021/acs.jmedchem.5b00099
    4. Wei Lv, Jinzhong Liu, Todd C. Skaar, David A. Flockhart, and Mark Cushman . Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities. Journal of Medicinal Chemistry 2015, 58 (6) , 2623-2648. https://doi.org/10.1021/jm501218e
    5. Berkley E. Gryder, Michael K. Rood, Kenyetta A. Johnson, Vishal Patil, Eric D. Raftery, Li-Pan D. Yao, Marcie Rice, Bahareh Azizi, Donald F. Doyle, and Adegboyega K. Oyelere . Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity. Journal of Medicinal Chemistry 2013, 56 (14) , 5782-5796. https://doi.org/10.1021/jm400467w
    6. Kinh-Luan Dao, Rupa R. Sawant, J. Adam Hendricks, Victoria Ronga, Vladimir P. Torchilin, and Robert N. Hanson . Design, Synthesis, and Initial Biological Evaluation of a Steroidal Anti-Estrogen–Doxorubicin Bioconjugate for Targeting Estrogen Receptor-Positive Breast Cancer Cells. Bioconjugate Chemistry 2012, 23 (4) , 785-795. https://doi.org/10.1021/bc200645n
    7. Abraham Nudelman. Mutual Prodrugs - Codrugs. Current Medicinal Chemistry 2023, 30 (38) , 4283-4339. https://doi.org/10.2174/0929867330666221209102650
    8. Purushottam Kapse, Rupesh V. Chikhale, Mohammad Rizwan Khan, Saikh M. Wabaidur, Md Ataul Islam. Synthesis of novel cycloheptylbenzothiazole-2-carboxamides and biological evaluation as human estrogen receptor modulators. Journal of Molecular Structure 2021, 1227 , 129516. https://doi.org/10.1016/j.molstruc.2020.129516
    9. Yonglong Jin, Yi Wang, Xiguang Liu, Jing Zhou, Xintong Wang, Hui Feng, Hong Liu. <p>Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers</p>. Drug Design, Development and Therapy 2020, Volume 14 , 5205-5215. https://doi.org/10.2147/DDDT.S260253
    10. Subhajit Makar, Tanmay Saha, Rayala Swetha, Gopichand Gutti, Ashok Kumar, Sushil K. Singh. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer. Bioorganic Chemistry 2020, 94 , 103380. https://doi.org/10.1016/j.bioorg.2019.103380
    11. L.A. Bulavin, N.A. Goncharenko, O.P. Dmytrenko, O.L. Pavlenko, M.P. Kulish, O. Goncharova, P.V. Demydov, A.M. Lopatynskyi, V.I. Chegel. Heteroassociation of antitumor agent doxorubicin with bovine serum albumin in the presence of gold nanoparticles. Journal of Molecular Liquids 2019, 284 , 633-638. https://doi.org/10.1016/j.molliq.2019.04.017
    12. Behdad Delavari, Fatemeh Mamashli, Bahareh Bigdeli, Atefeh Poursoleiman, Leila Karami, Zahra Zolmajd-Haghighi, Atiyeh Ghasemi, Samaneh Samaei-Daryan, Morteza Hosseini, Thomas Haertlé, Vladimir I. Muronetz, Øyvind Halskau, Ali Akbar Moosavi-Movahedi, Bahram Goliaei, Ali Hossein Rezayan, Ali Akbar Saboury. A biophysical study on the mechanism of interactions of DOX or PTX with α-lactalbumin as a delivery carrier. Scientific Reports 2018, 8 (1) https://doi.org/10.1038/s41598-018-35559-1
    13. Xiao Duan, Jianxin Chen, Yalan Wu, Si Wu, Dongyan Shao, Jie Kong. Drug Self‐Delivery Systems Based on Hyperbranched Polyprodrugs towards Tumor Therapy. Chemistry – An Asian Journal 2018, 13 (8) , 939-943. https://doi.org/10.1002/asia.201701697
    14. Sayyed Mostafa Habibi-Khorassani, Mehdi Shahraki, Elham Aghdaei, Bahareh Mostafa. Investigation of the Mannich reaction for generating a β -aminoketone: further treatment of kinetic results. Journal of Taibah University for Science 2018, 12 (1) , 46-55. https://doi.org/10.1080/16583655.2018.1451062
    15. Shagufta, Irshad Ahmad. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. European Journal of Medicinal Chemistry 2018, 143 , 515-531. https://doi.org/10.1016/j.ejmech.2017.11.056
    16. Weiwei Hu, Jian Zhao, Wuyang Hua, Shaohua Gou. A study on platinum( iv ) species containing an estrogen receptor modulator to reverse tamoxifen resistance of breast cancer. Metallomics 2018, 10 (2) , 346-359. https://doi.org/10.1039/C7MT00289K
    17. Xiao Duan, Ting Bai, Junjie Du, Jie Kong. One-pot synthesis of glutathione-responsive amphiphilic drug self-delivery micelles of doxorubicin–disulfide–methoxy polyethylene glycol for tumor therapy. Journal of Materials Chemistry B 2018, 6 (1) , 39-43. https://doi.org/10.1039/C7TB02817B
    18. Patrick Kelly, Niall Keely, Sandra Bright, Bassem Yassin, Gloria Ana, Darren Fayne, Daniela Zisterer, Mary Meegan. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation. Molecules 2017, 22 (9) , 1440. https://doi.org/10.3390/molecules22091440
    19. Niall Keely, Miriam Carr, Bassem Yassin, Gloria Ana, David Lloyd, Daniela Zisterer, Mary Meegan. Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold. Biomedicines 2016, 4 (3) , 15. https://doi.org/10.3390/biomedicines4030015
    20. Estelle Marchal, Md. Imam Uddin, Cassandra L.A. Hawco, Alison Thompson. Synthesis of prodigiosene–estrogen conjugates: optimization of protecting group strategies and anticancer properties. Canadian Journal of Chemistry 2015, 93 (5) , 526-535. https://doi.org/10.1139/cjc-2014-0516
    21. Gheorghe Roman. Mannich bases in medicinal chemistry and drug design. European Journal of Medicinal Chemistry 2015, 89 , 743-816. https://doi.org/10.1016/j.ejmech.2014.10.076
    22. Cassandra L.A. Hawco, Estelle Marchal, Md. Imam Uddin, Alexander E.G. Baker, Dale P. Corkery, Graham Dellaire, Alison Thompson. Synthesis and biological evaluation of prodigiosene conjugates of porphyrin, estrone and 4-hydroxytamoxifen. Bioorganic & Medicinal Chemistry 2013, 21 (19) , 5995-6002. https://doi.org/10.1016/j.bmc.2013.07.042
    23. Song Ding, Xin Qiao, Gregory L. Kucera, Ulrich Bierbach. Design of a platinum–acridine–endoxifen conjugate targeted at hormone-dependent breast cancer. Chemical Communications 2013, 49 (24) , 2415. https://doi.org/10.1039/c3cc38957j
    24. Reem I. Al-Wabli, Omaima M. AboulWafa, Khairia M. Youssef. Synthesis of curcumin and ethylcurcumin bioconjugates as potential antitumor agents. Medicinal Chemistry Research 2012, 21 (6) , 874-890. https://doi.org/10.1007/s00044-011-9587-3
    25. Robert N. Hanson, Edward Hua, David Labaree, Richard B. Hochberg, Kyle Proffitt, John M. Essigmann, Robert G. Croy. Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using “click” chemistry. Organic & Biomolecular Chemistry 2012, 10 (42) , 8501. https://doi.org/10.1039/c2ob25902h
    26. Laura Roca-Alonso, Loredana Pellegrino, Leandro Castellano, Justin Stebbing. Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms. Cardiology 2012, 122 (4) , 253-259. https://doi.org/10.1159/000339858
    27. Alvaro Mordente, Elisabetta Meucci, Andrea Silvestrini, Giuseppe Ettore Martorana, Bruno Giardina. Anthracyclines and Mitochondria. 2012, 385-419. https://doi.org/10.1007/978-94-007-2869-1_18
    28. Ahmed Kamal, M. Kashi Reddy, M. Janaki Ramaiah, Rajender, J. Surendranadha Reddy, Y.V.V. Srikanth, D. Dastagiri, E. Vijaya Bharathi, S.N.C.V.L. Pushpavalli, Pranjal Sarma, Manika Pal-Bhadra. Synthesis and biological evaluation of estradiol linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates as potential anticancer agents. Bioorganic & Medicinal Chemistry 2011, 19 (8) , 2565-2581. https://doi.org/10.1016/j.bmc.2011.03.015
    29. Amadou R. Yaya, Mohamed Touaibia, Gassan Massarweh, Fernande D. Rochon, Livain Breau. Synthesis of 17α-substituted ethynylestradiols: Potential ligands for drug vectors. Steroids 2010, 75 (7) , 489-498. https://doi.org/10.1016/j.steroids.2010.03.004
    30. Yong-Jiang Zhao, Wei Wei, Zhi-Guo Su, Guang-Hui Ma. Poly (ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: Design, synthesis and biological evaluation. International Journal of Pharmaceutics 2009, 379 (1) , 90-99. https://doi.org/10.1016/j.ijpharm.2009.06.013
    31. Carlos Olano, Carmen Méndez, José A. Salas. Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis. Natural Product Reports 2009, 26 (5) , 628. https://doi.org/10.1039/b822528a
    32. Hong-Li Hu, Hui Jiang, Xue-Mei Wang, Bao-An Chen. Detection and distinguishability of leukemia cancer cells based on Au nanoparticles modified electrodes. Electrochemistry Communications 2008, 10 (8) , 1121-1124. https://doi.org/10.1016/j.elecom.2008.05.030
    33. Dongxiao Sun, Arun K. Sharma, Ryan W. Dellinger, Andrea S. Blevins-Primeau, Renee M. Balliet, Gang Chen, Telih Boyiri, Shantu Amin, Philip Lazarus. Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases. Drug Metabolism and Disposition 2007, 35 (11) , 2006-2014. https://doi.org/10.1124/dmd.107.017145
    34. Naseem Ahmed, Celena Dubuc, Jacques Rousseau, Francois Bénard, Johan E. van Lier. Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates. Bioorganic & Medicinal Chemistry Letters 2007, 17 (11) , 3212-3216. https://doi.org/10.1016/j.bmcl.2007.03.016
    35. Ana Luísa Simplício, John M. Clancy, John F. Gilmer. β-Aminoketones as prodrugs with pH-controlled activation. International Journal of Pharmaceutics 2007, 336 (2) , 208-214. https://doi.org/10.1016/j.ijpharm.2006.11.055
    36. Suzanne M. Cutts, Lonnie P. Swift, Vinochani Pillay, Robert A. Forrest, Abraham Nudelman, Ada Rephaeli, Don R. Phillips. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Molecular Cancer Therapeutics 2007, 6 (4) , 1450-1459. https://doi.org/10.1158/1535-7163.MCT-06-0551
    37. Tad H. Koch, Benjamin L. Barthel, Brian T. Kalet, Daniel L. Rudnicki, Glen C. Post, David J. Burkhart. Anthracycline–Formaldehyde Conjugates and Their Targeted Prodrugs. 2007, 141-170. https://doi.org/10.1007/128_2007_4
    38. Jingyuan Li, Chunhui Wu, Feng Gao, Renyun Zhang, Gang Lv, Degang Fu, Baoan Chen, Xuemei Wang. In vitro study of drug accumulation in cancer cells via specific association with CdS nanoparticles. Bioorganic & Medicinal Chemistry Letters 2006, 16 (18) , 4808-4812. https://doi.org/10.1016/j.bmcl.2006.06.069
    39. Peter Feick, Stephan R.L. Haas, Manfred V. Singer, Ulrich Böcker. Low-dose exposure of intestinal epithelial cells to formaldehyde results in MAP kinase activation and molecular alteration of the focal adhesion protein paxillin. Toxicology 2006, 219 (1-3) , 60-72. https://doi.org/10.1016/j.tox.2005.11.004
    40. Hasrat Ali, Naseem Ahmed, Guillaume Tessier, Johan E. van Lier. Synthesis and biological activities of nucleoside–estradiol conjugates. Bioorganic & Medicinal Chemistry Letters 2006, 16 (2) , 317-319. https://doi.org/10.1016/j.bmcl.2005.10.004
    41. Suzanne Cutts, Abraham Nudelman, Ada Rephaeli, Don Phillips. The Power and Potential of Doxorubicin-DNA Adducts. IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) 2005, 57 (2) , 73-81. https://doi.org/10.1080/15216540500079093
    42. Véronique Gagnon, Marie-Ève St-Germain, Caroline Descôteaux, Josée Provencher-Mandeville, Sophie Parent, Sanat K. Mandal, Eric Asselin, Gervais Bérubé. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers—molecular modeling studies. Bioorganic & Medicinal Chemistry Letters 2004, 14 (23) , 5919-5924. https://doi.org/10.1016/j.bmcl.2004.09.015
    43. David J. Burkhart, Brian T. Kalet, Michael P. Coleman, Glen C. Post, Tad H. Koch. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Molecular Cancer Therapeutics 2004, 3 (12) , 1593-1604. https://doi.org/10.1158/1535-7163.1593.3.12
    44. Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews 2004, 56 (2) , 185-229. https://doi.org/10.1124/pr.56.2.6

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect